Recombinant DNA technology may enable oral, rather than injectable, delivery of pro...( ently injectable protein drugs such as ...)

Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs

ently injectable protein drugs such as insulin, growth hormone, and erythropoietin, a medication to increase red blood cell counts."

Recombinant DNA technology has and will enable the pharmaceutical industry to produce safer, more pure and more effective versions of therapeutic proteins, Shen adds.

"Since recombinant therapeutics utilize human proteins, they do not induce an unwanted immune response like products created from non-human sources often do."

On behalf of Shen and his collaborators, USC holds the patent to the new recombinant fusion protein technology. The research was supported by grants from the National Institutes of Health.

'"/>

Contact: Sarah Huoh
shuoh@usc.edu
323-442-2830
University of Southern California
6-May-2005

Page: 1 2 3
Related medicine news :

1. Wireless technology shows promise in diagnosing pediatric intestinal disease
2. Speeding up CT scans with cellphone technology, ultrasound warning signal for breast cancer
3. E/Tablet technology may provide benefits to patients, researchers
4. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
5. SCAI highlights study using wireless technology to speed care of heart attack patients
6. UQ research heralds vaccine technology breakthrough
7. Plasmonics book gives overview of technology that could revolutionize computing
8. New biotech company to commercialize novel UD gene-repair technology
9. ACP supports new bill to promote adoption of health information technology
10. Adoption of health information technology will lead to higher standard of quality care
11. Research agreement to advance new imaging technology

Post Your Comments:

(Date:5/19/2013)... May 19, 2013 The report “Feed ... Trends & Forecasts up to 2017” published by MarketsandMarkets, ... with analysis and forecasting of the global volume and ... the driving and restraining factors for the global market ... and challenges. The market is segmented and revenue is ...

(Date:5/19/2013)... 19, 2013 Farming methods have changed ... the ground 10,000 years ago. Most recently, the Green ... by using genetically engineered seeds and by applying chemical ... backlash to these techniques due to the adverse environmental ... a corresponding surge in interest in organic, sustainable farming ...

(Date:5/19/2013)... (PRWEB) May 19, 2013 Yeast infections are ... appear in sensitive areas of the human body. A new ... This new formula provides a unique method of application to ... spray solution is now provided to men and women searching ... naturally absorbed in the body through food and is stored ...

(Date:5/19/2013)... (PRWEB) May 19, 2013 Beginning Wednesday, May ... Valley Blood Center (RRVBC) will feature “Hot Dog Wednesdays" and ... RRVBC will provide hot dogs and all the fixin's ... slushies each day throughout the summer. “Donors are our lifeline. ... a stable and adequate blood supply. This is a ...

(Date:5/19/2013)... Minor fender benders and serious car ... parties to the accident to respond appropriately to the ... Prevention (CDC) data from 2010, accidents, including car accidents, ... In fact, in 2005, automobile accident-related deaths ... than 2.3 million drivers and passengers receive treatment in ...

Breaking Medicine News(10 mins):Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2 Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3 Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2 Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3 Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2 Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2 Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2

[0] Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets [0] Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics [0] A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount [0] Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer [0] Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash

(Date:5/18/2013)... NEW YORK , May 18, 2013 /PRNewswire/ ... securities law firm, is investigating potential securities fraud ... (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ... the Company and its executives violated federal securities ... regarding the Company,s Phase III drug trials for ...

(Date:5/17/2013)... 2013 Medical devices are any medical items ... In light of their different mechanisms, actions and regulatory ... complicated than drug trails due to their unique clinical ... of evaluating both safety and efficacy (which is left ... the same as the SFDA) evaluate MDs for both ...

(Date:5/17/2013)... Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) ... Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from ... (NIAID), a division of the National Institutes of ... antibody therapeutics to combat Staphylococcus aureus ... methicillin-resistant S. aureus (MRSA), was renewed ...

Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2 Statistical Challenges in Medical Device Trail Evaluation 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4

[0] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm [0] Statistical Challenges in Medical Device Trail Evaluation [0] Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases